Evaluation of the relation between subclinical systolic dysfunction defined by four-dimensional speckle-tracking echocardiography and growth differentiation factor-15 levels in patients with acromegaly.
Acromegaly
Framingham Cardiovascular Risk score
GDF-15
Left ventricular strain
Speckle tracking echocardiography
Journal
Hormones (Athens, Greece)
ISSN: 2520-8721
Titre abrégé: Hormones (Athens)
Pays: Switzerland
ID NLM: 101142469
Informations de publication
Date de publication:
18 Apr 2024
18 Apr 2024
Historique:
received:
24
12
2023
accepted:
01
04
2024
medline:
18
4
2024
pubmed:
18
4
2024
entrez:
17
4
2024
Statut:
aheadofprint
Résumé
In patients with acromegaly, the long-term presence of elevated GH and IGF-1 levels is associated with an unfavorable cardiovascular risk profile. We aimed to assess the relationship of four-dimensional speckle tracking echocardiographic (4DSTE) measurements with growth differentiation factor-15 (GDF-15) levels and the Framingham Cardiovascular Risk Score (FRS) in patients with acromegaly. A single-center, cross-sectional study was conducted. The study included 40 acromegaly and 32 age- and gender-matched controls. Anthropometric, biochemical, and echocardiographic assessments were performed. GDF-15 levels were measured using ELISA. In the controlled acromegaly group, global longitudinal (GLS), circumferential (GCS), area (GAS), and radial (GRS) strain measurements identified by 4DSTE were lower than those of the controls (p < 0.05). Moreover, strain parameters were lower in active acromegaly patients than in controls, but the difference was not statistically significant. The GLS was negatively correlated with age, the estimated disease duration, and FRS. Serum GDF-15 levels showed no significant difference between the acromegaly and control groups. In patients with acromegaly, serum GDF-15 levels were positively correlated with age, waist-to-hip ratio, systolic and diastolic blood pressure, FRS, fasting plasma glucose, and HbA1c, but not with strain parameters. The multiple regression analysis revealed that FRS was an independent factor associated with serum GDF-15 levels in patients with acromegaly and the overall cohort (p < 0.001). Our study demonstrates that while LVEF was within normal limits, global strain parameters (GLS, GCS, GAS, and GRS) measured by using a novel imaging technique, 4DSTE, were lower in patients with acromegaly, suggesting the presence of subclinical systolic dysfunction in patients with acromegaly. GDF-15 can be a potential predictor of cardiovascular risk in patients with acromegaly.
Identifiants
pubmed: 38632216
doi: 10.1007/s42000-024-00558-7
pii: 10.1007/s42000-024-00558-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Hacettepe Üniversitesi
ID : THD-2019-18223
Informations de copyright
© 2024. The Author(s), under exclusive licence to Hellenic Endocrine Society.
Références
Hong S, Kim KS, Han K et al (2022) Acromegaly and cardiovascular outcomes: a cohort study. Eur Heart J 43:1491–1499. https://doi.org/10.1093/eurheartj/ehab822
doi: 10.1093/eurheartj/ehab822
pubmed: 34864952
Akgul E, Tokgozoglu SL, Erbas T et al (2010) Evaluation of the impact of treatment on endothelial function and cardiac performance in acromegaly. Echocardiography 27:990–996. https://doi.org/10.1111/j.1540-8175.2010.01179.x
doi: 10.1111/j.1540-8175.2010.01179.x
pubmed: 20412263
Sendur SN, Hazirolan T, Aydin B et al (2022) Specific FSTL1 polymorphism may determine the risk of cardiomyopathy in patients with acromegaly. Acta Cardiol 77:350–359. https://doi.org/10.1080/00015385.2021.1948206
doi: 10.1080/00015385.2021.1948206
pubmed: 34233581
Chiloiro S, Giampietro A, Gagliardi I et al (2022) Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience. Pituitary 25:831–841. https://doi.org/10.1007/s11102-022-01266-4
doi: 10.1007/s11102-022-01266-4
pubmed: 35922724
pmcid: 9362053
Kempf T, Eden M, Strelau J et al (2006) The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 98:351–360. https://doi.org/10.1161/01.Res.0000202805.73038.48
doi: 10.1161/01.Res.0000202805.73038.48
pubmed: 16397141
Wang D, Day EA, Townsend LK et al (2021) GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nat Rev Endocrinol 17:592–607. https://doi.org/10.1038/s41574-021-00529-7
doi: 10.1038/s41574-021-00529-7
pubmed: 34381196
Xanthakis V, Larson MG, Wollert KC et al (2013) Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. J Am Heart Assoc 2:e000399. https://doi.org/10.1161/jaha.113.000399
doi: 10.1161/jaha.113.000399
pubmed: 24200688
pmcid: 3886765
Xu J, Kimball TR, Lorenz JN et al (2006) GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98:342–350. https://doi.org/10.1161/01.RES.0000202804.84885.d0
doi: 10.1161/01.RES.0000202804.84885.d0
pubmed: 16397142
Santhanakrishnan R, Chong JP, Ng TP et al (2012) Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 14:1338–1347. https://doi.org/10.1093/eurjhf/hfs130
doi: 10.1093/eurjhf/hfs130
pubmed: 22869458
Fang S, Zhang Z, Wang Y et al (2019) Predictive value of left ventricular myocardial strain by four-dimensional speckle tracking echocardiography combined with red cell distribution width in heart failure with preserved ejection fraction. Echocardiography 36:1074–1083. https://doi.org/10.1111/echo.14373
doi: 10.1111/echo.14373
pubmed: 31162738
Kalam K, Otahal P, Marwick TH (2014) Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart 100:1673–1680. https://doi.org/10.1136/heartjnl-2014-305538
doi: 10.1136/heartjnl-2014-305538
pubmed: 24860005
Volschan ICM, Kasuki L, Silva CMS et al (2017) Two-dimensional speckle tracking echocardiography demonstrates no effect of active acromegaly on left ventricular strain. Pituitary 20:349–357. https://doi.org/10.1007/s11102-017-0795-9
doi: 10.1007/s11102-017-0795-9
pubmed: 28220351
Popielarz-Grygalewicz A, Stelmachowska-Banaś M, Gąsior JS et al (2020) Subclinical left ventricular systolic dysfunction in patients with naive acromegaly - assessment with two-dimensional speckle-tracking echocardiography: retrospective study. Endokrynol Pol 71:227–234. https://doi.org/10.5603/EP.a2020.0021
doi: 10.5603/EP.a2020.0021
pubmed: 32293699
Gadelha P, Santos ECL, Castillo J et al (2022) Subclinical ventricular dysfunction in long-term acromegaly assessed by Speckle-Tracking Echocardiography. Front Endocrinol (Lausanne) 13:812964. https://doi.org/10.3389/fendo.2022.812964
doi: 10.3389/fendo.2022.812964
pubmed: 35185796
Giustina A, Chanson P, Bronstein MD et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141–3148. https://doi.org/10.1210/jc.2009-2670
doi: 10.1210/jc.2009-2670
pubmed: 20410227
Hussein Z, Slack RW, Marcus HJ et al (2023) Post-operative medium- and long-term endocrine outcomes in patients with Non-functioning Pituitary Adenomas-Machine Learning Analysis. Cancers (Basel) 15. https://doi.org/10.3390/cancers15102771
Williams B, Mancia G, Spiering W et al (2018) 2018 ESC/ESH guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 39:3021–3104. https://doi.org/10.1093/eurheartj/ehy339
doi: 10.1093/eurheartj/ehy339
pubmed: 30165516
Classification and Diagnosis of Diabetes Standards of Medical Care in Diabetes-2019. Diabetes Care 42:S13–s28. https://doi.org/10.2337/dc19-S002
D’agostino RB, Sr., Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117:743–753. https://doi.org/10.1161/circulationaha.107.699579
doi: 10.1161/circulationaha.107.699579
pubmed: 18212285
Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463. https://doi.org/10.1016/j.echo.2005.10.005
doi: 10.1016/j.echo.2005.10.005
pubmed: 16376782
Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16:233–270. https://doi.org/10.1093/ehjci/jev014
doi: 10.1093/ehjci/jev014
pubmed: 25712077
Muraru D, Niero A, Rodriguez-Zanella H et al (2018) Three-dimensional speckle-tracking echocardiography: benefits and limitations of integrating myocardial mechanics with three-dimensional imaging. Cardiovasc Diagn Ther 8:101–117. https://doi.org/10.21037/cdt.2017.06.01
doi: 10.21037/cdt.2017.06.01
pubmed: 29541615
pmcid: 5835646
Lang RM, Badano LP, Tsang W et al (2012) EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. Eur Heart J Cardiovasc Imaging 13:1–46. https://doi.org/10.1093/ehjci/jer316
doi: 10.1093/ehjci/jer316
pubmed: 22275509
Jayasena CN, Comninos AN, Clarke H et al (2011) The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol (Oxf) 75:220–225. https://doi.org/10.1111/j.1365-2265.2011.04019.x
doi: 10.1111/j.1365-2265.2011.04019.x
pubmed: 21521288
Colao A, Marzullo P, Cuocolo A et al (2003) Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 58:169–176. https://doi.org/10.1046/j.1365-2265.2003.01689.x
doi: 10.1046/j.1365-2265.2003.01689.x
pubmed: 12580932
Fung MJ, Leung DY, Thomas L (2018) Differential Myocardial Fibre involvement by Strain Analysis in patients with aortic stenosis. Heart Lung Circ 27:1357–1367. https://doi.org/10.1016/j.hlc.2017.08.017
doi: 10.1016/j.hlc.2017.08.017
pubmed: 28966113
Jurcut R, Găloiu S, Florian A et al (2014) Quantifying subtle changes in cardiovascular mechanics in acromegaly: a Doppler myocardial imaging study. J Endocrinol Invest 37:1081–1090. https://doi.org/10.1007/s40618-014-0147-9
doi: 10.1007/s40618-014-0147-9
pubmed: 25125022
Seferović PM, Petrie MC, Filippatos GS et al (2018) Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 20:853–872. https://doi.org/10.1002/ejhf.1170
doi: 10.1002/ejhf.1170
pubmed: 29520964
Minciună IA, Hilda Orășan O, Minciună I et al (2021) Assessment of subclinical diabetic cardiomyopathy by speckle-tracking imaging. Eur J Clin Invest 51:e13475. https://doi.org/10.1111/eci.13475
doi: 10.1111/eci.13475
pubmed: 33326612
Ghoreyshi-Hefzabad SM, Jeyaprakash P, Vo HQ et al (2023) Subclinical systolic dysfunction detected by 2D speckle tracking echocardiography in adults with diabetes mellitus: systematic review and meta-analysis of 6668 individuals with diabetes mellitus and 7218 controls. Int J Cardiovasc Imaging 39:977–989. https://doi.org/10.1007/s10554-023-02810-4
doi: 10.1007/s10554-023-02810-4
pubmed: 36995526
pmcid: 10160195
Gao J, Xu M, Gong M et al (2023) Left ventricular longitudinal strain in patients with type 2 diabetes mellitus is independently associated with glycated hemoglobin level. Clin Cardiolhttps://doi. https://doi.org/10.1002/clc.24136
doi: 10.1002/clc.24136
Jabbar A, Pingitore A, Pearce SH et al (2017) Thyroid hormones and cardiovascular disease. Nat Rev Cardiol 14:39–55. https://doi.org/10.1038/nrcardio.2016.174
doi: 10.1038/nrcardio.2016.174
pubmed: 27811932
Kong LY, Gao X, Ding XY et al (2019) Left ventricular end-diastolic strain rate recovered in hypothyroidism following levothyroxine replacement therapy: a strain rate imaging study. Echocardiography 36:707–713. https://doi.org/10.1111/echo.14307
doi: 10.1111/echo.14307
pubmed: 30834590
Huang WH, Sung KT, Kuo JY et al (2021) Atrioventricular longitudinal mechanics using Novel Speckle-Tracking Improved Risk Stratification Beyond baseline thyroid hormone in asymptomatic subclinical hypothyroidism. Circ Cardiovasc Imaging 14:e012433. https://doi.org/10.1161/circimaging.121.012433
doi: 10.1161/circimaging.121.012433
pubmed: 34784240
Wallentin L, Hijazi Z, Andersson U et al (2014) Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for reduction in stroke and other thromboembolic events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 130:1847–1858. https://doi.org/10.1161/circulationaha.114.011204
doi: 10.1161/circulationaha.114.011204
pubmed: 25294786
Shin MY, Kim JM, Kang YE et al (2016) Association between growth differentiation factor 15 (GDF15) and Cardiovascular Risk in patients with newly diagnosed type 2 diabetes Mellitus. J Korean Med Sci 31:1413–1418. https://doi.org/10.3346/jkms.2016.31.9.1413
doi: 10.3346/jkms.2016.31.9.1413
pubmed: 27510384
pmcid: 4974182
Hong JH, Chung HK, Park HY et al (2014) GDF15 is a novel biomarker for impaired fasting glucose. Diabetes Metab J 38:472–479. https://doi.org/10.4093/dmj.2014.38.6.472
doi: 10.4093/dmj.2014.38.6.472
pubmed: 25541611
pmcid: 4273034
Xie S, Lu L, Liu L (2019) Growth differentiation factor-15 and the risk of cardiovascular diseases and all-cause mortality: a meta-analysis of prospective studies. Clin Cardiol 42:513–523. https://doi.org/10.1002/clc.23159
doi: 10.1002/clc.23159
pubmed: 30697778
pmcid: 6523003
Natali A, Nesti L, Venturi E et al (2019) Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: a nested, case-control study. Diabetes Obes Metab 21:412–416. https://doi.org/10.1111/dom.13519
doi: 10.1111/dom.13519
pubmed: 30178545